Clinical Trials Logo

Clinical Trial Summary

The study is a two-stage trial: 1. First stage (closed - 16 patients recruited in France): Phase I feasibility trial to evaluate the safety of the combination of Nivolumab + metronomic chemotherapy considering three possible metronomic chemotherapy regimens 2. Second stage (opened - 86 patients expected in France and Belgium): Phase II randomized controlled balanced 1:1 open-label trial comparing the efficacy of the metronomic chemotherapy regimen selected at the end of the previous stage (arm C: cyclophosphamide, capecitabine, vinblastine), with or without nivolumab. 3. "Trans-MetroPD1" ancillary sub-study is partially implemented since April 2022, and proposed to patients participating to second stage


Clinical Trial Description

1. First stage (closed): - Arm A: Nivolumab + Cyclophosphamide-Vinblastine - Arm B: Nivolumab + Capecitabin - Arm C: Nivolumab + Cyclophosphamide-Vinblastine + Capecitabin Arm A and Arm B have been allocated sequentially (A/B/A/B/A/B). Arm C has been opened, since arm A and Arm B were deemed safe. In each arm, the second patient was not recruited before the first patient has been observed for a 28-day duration. 2. Second stage (opened): Following the analysis of safety data from first stage, and according to IDMC's recommendations on December 2020, the metronomic chemotherapy selected for second stage was arm C: cyclophosphamide, capecitabine, vinblastine Randomization will be balanced 1:1, controlling for: - histological type: embryonal brain tumor, ependymoma, low-grade glioma, rhabdomyosarcoma, neuroblastoma, Ewing sarcoma, and other solid tumors after approval from coordinators, - and treating center, using a dynamic allocation of treatment (minimization program) with a random factor set at 0.8. 3. Trans-MetroPD1 is divided into 3 axes: - to evaluate the health-related quality of life - to measure the kinectis of progastrin/hPG80, a biomarker over-expressed in a wide range of cancers - to determine the distribution of immune cells within blood tissue ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03585465
Study type Interventional
Source Centre Oscar Lambret
Contact
Status Active, not recruiting
Phase Phase 1/Phase 2
Start date March 26, 2019
Completion date January 2028

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03336931 - PRecISion Medicine for Children With Cancer
Completed NCT03430752 - Comparing the Impact of Cancer on Quality of Life Between Survivors of Childhood Solid Tumors and Leukemia
Recruiting NCT01620372 - French Childhood Cancer Survivor Study N/A
Not yet recruiting NCT06208657 - Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer Phase 1/Phase 2
Recruiting NCT01919866 - Safety Study of CD3/CD19 Depleted Haploidentical Stem Cells Phase 1/Phase 2
Terminated NCT01337544 - Haploidentical Stem Cell Transplantation and IL-15 NK Cell Infusion for Paediatric Refractory Solid Tumours Phase 1/Phase 2
Completed NCT02533895 - Cancer Immune Therapy for the Treatment of Refractory Solid Tumours of Childhood Phase 1
Active, not recruiting NCT03445858 - Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults Early Phase 1
Recruiting NCT05504772 - Precision Medicine for Every Child With Cancer
Terminated NCT02624388 - Study of Genistein in Pediatric Oncology Patients (UVA-Gen001) Phase 2
Completed NCT01670175 - Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors Phase 1
Completed NCT03206021 - COZMOS:Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain/Solid Tumors Phase 1